

5<sup>th</sup> February 2020

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 <sup>th</sup> Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
---	---

**Re: Outcome of the Board Meeting**

Dear Sir/Madam,

At the Board meeting held today, the Board has inter alia approved and taken on record Unaudited Financial results for the third quarter ended 31<sup>st</sup> December 2019. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

Please find enclosed herewith following:

- i. Press Release being issued on the Results for the third quarter ended 31<sup>st</sup> December 2019;
- ii. Unaudited Consolidated Financial Results for the third quarter ended 31<sup>st</sup> December 2019;
- iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the third quarter ended 31<sup>st</sup> December 2019;
- iv. Unaudited Standalone Financial Results for the third quarter ended 31<sup>st</sup> December 2019;
- v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the third quarter ended 31<sup>st</sup> December 2019.

Kindly note that the meeting of the Board of Directors commenced at 3.30 p.m. and concluded at 5.45 p.m.

Kindly take the above on your records.

Thanking You,

Yours faithfully,

  
**GAURANG SHAH**

AVP - Legal &amp; Company Secretary

Encl.: a/a

Press Release**Revenue from operation in Q3 up by 34%**  
(3<sup>rd</sup> Quarter & 9 Months, FY 2020 Consolidated Results)

**Mumbai, 5<sup>th</sup> February, 2020:** Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 3<sup>rd</sup> quarter & 9 months ended 31<sup>st</sup> December 2019.

**Q3 FY 2020 performance highlights (compared to Q3 FY 2019)**

- Revenue from operation at Rs. 651 cr. against Rs. 485 cr., up 34%.
- EBITDA at Rs. 186 cr. against Rs. 107 cr., up 73%; EBITDA at 29% of revenue from operation.
- Profit after tax at Rs. 108 cr. against Rs. 67 cr., up 61%; PAT at 17% of revenue from operation.

**9 Months FY 2020 performance highlights (compared to 9 months FY 2019)**

- Revenue from operation at Rs. 1,906 cr. against Rs. 1,540 cr., up 24%.
- EBITDA at Rs. 540 cr. against Rs. 431 cr., up 25%; EBITDA at 28% of revenue from operation.
- Profit after tax at Rs. 339 cr. against Rs. 298 cr., up 14%; PAT at 18% of revenue from operation.

**India**

Q3 FY 2020, India sales was Rs. 195 cr. (against Rs. 174 cr.), up 12%. 9 Months FY 2020, India sales was Rs. 592 cr. (against Rs. 531 cr.) posting growth of 12%.

As per Iqvia MAT December 2019, we have posted healthy growth of 13% in Cardiology (segment growth of 11%), 17% in Ophthalmology (segment growth of 10%), 9% in Dermatology (segment growth of 9%) and 17% in Pain Management (segment growth of 12%).

**Exports**

Q3 FY 2020, total export sales were Rs. 448 cr. (against Rs. 304 cr.) posting growth of 47%.

- Emerging Market branded generic sales was Rs. 240 cr. (against Rs. 188 cr.) posting 28% growth. Out of which:
  - Africa branded generic sales was Rs. 80 cr. (against Rs. 64 cr.) posting 25% growth.
  - Asia branded generic sales was Rs. 158 cr. (against Rs. 121 cr.) posting 30% growth.
- US generic sales was Rs. 159 cr. (against Rs. 66 cr.) posting 140% growth.
- Africa Institution sales was Rs. 49 cr. (against Rs. 50 cr.) posting 2% de-growth.

9 Months FY 2020, total export sales were Rs. 1,300 cr. (against Rs. 981 cr.) posting growth of 32%.

- Emerging Market branded generic sales was Rs. 726 cr. (against Rs. 625 cr.) posting 16% growth. Out of which:
  - Africa branded generic sales was Rs. 254 cr. (against Rs. 232 cr.) posting 9% growth.
  - Asia branded generic sales was Rs. 465 cr. (against Rs. 385 cr.) posting 21% growth.
- US generic sales was Rs. 372 cr. (against Rs. 207 cr.) posting 80% growth.
- Africa Institution sales was Rs. 202 cr. (against Rs. 149 cr.) posting 35% growth.

In US, during **9 Months** FY 2020, we received 7 ANDA final approval, 1 tentative approval and filed 8 ANDA with US FDA. Out of 31 final ANDA approvals, we have commercialized 28 products. We hold 1 tentative approvals and 23 ANDAs are awaiting US FDA approval. Company plans to file 10-12 ANDAs during this financial year.

## **R&D**

---

During Q3 FY 2020, R&D expenses were Rs. 35 cr., (Q3 FY 2019 Rs. 45 cr.) which is 5% of operating revenue. During 9 Months FY 2020, R&D expenses were Rs. 114 cr., (9 Months FY 2019 Rs. 136 cr.) which is 6% of operating revenue.

## **About Ajanta Pharma Limited**

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1<sup>st</sup> to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai, having a team of 650+ scientists. Company has 8 world class manufacturing facilities (including one newly operationalised at Pithampur) located in India and Mauritius.

For last 10 financial years, company has posted healthy performance with its consolidated total income growing at 20% CAGR and net profit at 31% CAGR.

For more details visit [www.ajantapharma.com](http://www.ajantapharma.com)

For regular updates follow us on twitter– [www.twitter.com/ajantapharmaltd](https://www.twitter.com/ajantapharmaltd)

## **For specific queries, contact:**

Rajeev Agarwal Tel: +91 22 66061377 Email: [rajeev.agarwal@ajantapharma.com](mailto:rajeev.agarwal@ajantapharma.com)

Abhineet Kumar Tel: +91 22 66061814 Email: [abhineet.kumar@ajantapharma.com](mailto:abhineet.kumar@ajantapharma.com)

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331  
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement

**Limited review report on Unaudited Quarterly and year-to-date consolidated financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of  
Ajanta Pharma Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Ajanta Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2019 and year to date results for the period from 1 April 2019 to 31 December 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Ajanta Pharma (Mauritius) Ltd.	Subsidiary
Ajanta Pharma USA Inc.	Subsidiary
Ajanta Pharma Philippines Inc.	Subsidiary
Ajanta Pharma Nigeria Ltd.	Subsidiary
Ajanta Pharma (Mauritius) Intl. Ltd.	Subsidiary

*SRM*

**Limited review report on Unaudited Quarterly and year-to-date consolidated financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)**

**Ajanta Pharma Limited**

5. *As more fully explained in note 7 to the statement, the Group has recognised a write down of Rs. 7.19 crore with respect to inventories and of Rs. 16.08 crore with respect to property, plant and equipment on account of fire and certain other incidents at one of its manufacturing plants. The Group has also recognised a credit of Rs. 21.86 crore for insurance claim against the said losses. At the present stage of the processing of claim, we are unable to obtain sufficient appropriate evidence regarding the extent to which the insurance claim is reasonably certain to be accepted by the insurance Company. Consequently, we are unable to determine the extent to which adjustments to the financial results are necessary.*
6. Based on our review conducted and procedures performed as stated in paragraph 3 and except for the possible effects of the matter described in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes the interim financial information of two subsidiaries which have not been reviewed, whose interim financial information reflect total revenue of Rs. 49.67 crore and Rs. 153.84 crore, total net profit after tax of Rs. 7.85 crore and Rs. 24.60 crore and total comprehensive income of Rs. 12.80 crore and Rs. 29.55 crore for the quarter ended 31 December 2019 and for the period from 1 April 2019 to 31 December 2019, respectively, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022



**Sreeja Marar**

Partner

Mumbai  
5 February 2020

Membership No: 111410  
UDIN: 20111410AAAAAG8934



**Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2019**

₹ in Crore

Particulars	3 months ended			9 months ended		Year Ended
	31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Income</b>						
Revenue from operations	651.21	642.76	485.11	1,905.91	1,540.21	2,055.37
Other income	14.64	13.22	4.41	35.50	19.45	21.08
<b>Total Income</b>	<b>665.85</b>	<b>655.98</b>	<b>489.52</b>	<b>1,941.41</b>	<b>1,559.66</b>	<b>2,076.45</b>
<b>Expenses</b>						
Cost of materials consumed	138.34	124.28	81.97	386.80	265.02	391.84
Purchases of stock-in-trade	24.15	24.54	7.29	82.44	36.60	48.25
Changes in inventories of finished goods, work-in-progress and stock-in-trade	6.60	17.66	8.63	8.87	(23.67)	(56.61)
Employee benefits expense	120.38	117.41	112.78	356.11	323.31	430.71
Finance costs	1.57	4.93	0.09	8.29	0.39	1.16
Depreciation and amortisation expense	23.60	23.30	18.67	69.68	53.33	72.08
Other expenses	175.77	181.23	167.13	539.70	499.60	674.75
<b>Total Expenses</b>	<b>490.41</b>	<b>493.35</b>	<b>396.56</b>	<b>1,451.89</b>	<b>1,154.58</b>	<b>1,562.18</b>
<b>Profit before exceptional items and tax</b>	<b>175.44</b>	<b>162.63</b>	<b>92.96</b>	<b>489.52</b>	<b>405.08</b>	<b>514.27</b>
<b>Exceptional Item</b>						
Exceptional Item (Refer note 7)	0.34	1.07	-	1.41	-	-
<b>Profit before tax</b>	<b>175.10</b>	<b>161.56</b>	<b>92.96</b>	<b>488.11</b>	<b>405.08</b>	<b>514.27</b>
<b>Tax Expense</b>						
Current Tax	63.44	40.18	23.40	136.82	110.58	123.86
Deferred Tax	4.11	5.02	2.66	12.75	(3.58)	3.44
<b>Profit for the period</b>	<b>107.55</b>	<b>116.36</b>	<b>66.90</b>	<b>338.54</b>	<b>298.08</b>	<b>386.97</b>
<b>Other Comprehensive Income (OCI)</b>						
Items that will be reclassified subsequently to profit or loss	2.57	1.31	0.13	2.90	(2.20)	(1.95)
Income tax relating to Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Items that will not to be reclassified subsequently to profit or loss	(1.14)	(1.80)	(0.50)	(3.43)	(1.49)	(1.97)
Income tax relating to items that will not be reclassified to profit or loss	0.40	0.63	0.18	1.20	0.52	0.69
<b>Other Comprehensive Income for the year, net of tax</b>	<b>1.83</b>	<b>0.14</b>	<b>(0.19)</b>	<b>0.67</b>	<b>(3.17)</b>	<b>(3.23)</b>
<b>Total Comprehensive Income for the period</b>	<b>109.38</b>	<b>116.50</b>	<b>66.71</b>	<b>339.21</b>	<b>294.91</b>	<b>383.74</b>
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.54	17.54	17.69	17.54	17.69	17.54
Other Equity						2,227.67
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	12.33	13.34	7.60	38.80	33.87	43.97
(b) Diluted - in ₹	12.32	13.33	7.60	38.79	33.86	43.96

**Notes :**

- The above consolidated results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 5 February 2020.
- Statutory Auditors have carried out Limited Review of the consolidated financial results for the quarter and nine month ended 31 December 2019.
- The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- During the quarter, Nil (nine month 7,500) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ Nil (nine month ₹ 15,000) and securities premium account by ₹ Nil (nine month ₹ 0.93 crores).
- The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- The Group has adopted the modified retrospective approach as per Ind AS 116 - Leases to account for its leases, effective from reporting periods beginning 1 April 2019. This has resulted in recognising right of use assets of ₹ 34.97 crores and a corresponding lease liability of ₹ 39.02 crores by adjusting retained earnings by ₹ 2.65 crores (net of deferred tax of ₹ 1.40 crores) as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from rent to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. Due to this change, current quarter profit before tax is lower by ₹ Nil (nine month ₹ 0.17 crores). To this extent, performance for the current period ended 31 December 2019 is not comparable with previous period results.
- Pursuant to a fire incident on 31 August 2019 at Guwahati plant, certain property, plant and equipment and inventory were damaged. The Company has lodged an initial estimate of loss with the insurance company and the survey is currently in process. The Company has recorded a loss of ₹ 23.27 crores towards impairment of part of property, plant and equipment and inventory arising from the incident. The Company has also recognised a minimum insurance claim receivable of ₹ 21.86 crores in the current nine month, for which auditor has given modified opinion. However, Company is confident of receiving the said claim. The aforementioned loss and the income from insurance claim receivable has been presented under exceptional item in the financial result with a net impact of ₹ 1.41 crores. The Company is in process of determining its final claim and will make adjustments to the estimated loss when the assessment is completed.
- Figures for the previous period's have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The Standalone Financial Results are available on the company's website [www.ajantapharma.com](http://www.ajantapharma.com).

By order of the Board  
For Ajanta Pharma Ltd.

Yogesh M. Agrawal  
Managing Director

Mumbai, 5 February 2020



# B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011  
India

Telephone +91 (22) 4345 5300  
Fax +91 (22) 4345 5399

## Limited review report on unaudited quarterly and year-to-date standalone results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

### To the Board of Directors of Ajanta Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Ajanta Pharma Limited ('the Company') for the quarter ended 31 December 2019 and year to date results for the period from 1 April 2019 to 31 December 2019 ('the Statement').
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. *As more fully explained in note 7 to the statement, the Company has recognised a write down of Rs 7.19 crore with respect to inventories and of Rs 16.08 crore with respect to property, plant and equipment on account of fire and certain other incidents at one of its manufacturing plants. The Company has also recognised a credit of Rs 21.86 crore for insurance claim against the said losses. At the present stage of the processing of claim, we are unable to obtain sufficient appropriate evidence regarding the extent to which the insurance claim is reasonably certain to be accepted by the insurance company. Consequently, we are unable to determine the extent to which adjustments to the financial results are necessary.*

SKM

**Limited review report on unaudited quarterly and year-to-date standalone results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)**

**Ajanta Pharma Limited**

5. Based on our review conducted as above and except for the possible effects of the matter described in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No: 101248W/W-100022



**Sreeja Marar**

*Partner*

Mumbai

5 February 2020

Membership No: 111410

UDIN: 20111410AAAAAF3252



**Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December 2019**

Particulars	3 months ended			9 months ended		₹ in Crore
	31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	Year Ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	31/03/2019
<b>Income</b>						
Revenue from operations	530.55	559.45	451.85	1,635.74	1,359.09	1,772.62
Other income	51.17	39.31	12.97	130.10	98.96	102.15
<b>Total Income</b>	<b>581.72</b>	<b>598.76</b>	<b>464.82</b>	<b>1,765.84</b>	<b>1,458.05</b>	<b>1,874.77</b>
<b>Expenses</b>						
Cost of materials consumed	137.00	123.14	81.01	383.93	262.36	388.71
Purchases of stock-in-trade	24.82	22.29	18.05	75.74	49.11	70.79
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3.80)	26.09	5.48	33.36	(31.34)	(67.38)
Employee benefits expense	107.02	106.17	100.13	320.56	292.29	389.37
Finance costs	0.84	4.24	0.03	6.17	0.21	0.41
Depreciation and amortisation expense	22.50	22.19	18.28	66.40	51.70	69.90
Other expenses	127.23	132.74	116.14	395.22	372.68	509.92
<b>Total Expenses</b>	<b>415.61</b>	<b>436.86</b>	<b>339.12</b>	<b>1,281.38</b>	<b>997.01</b>	<b>1,361.72</b>
<b>Profit before exceptional items and tax</b>	<b>166.11</b>	<b>161.90</b>	<b>125.70</b>	<b>484.46</b>	<b>461.04</b>	<b>513.05</b>
<b>Exceptional Item</b>						
Exceptional Item (Refer note 7)	0.34	1.07	-	1.41	-	-
<b>Profit before tax</b>	<b>165.77</b>	<b>160.83</b>	<b>125.70</b>	<b>483.05</b>	<b>461.04</b>	<b>513.05</b>
<b>Tax Expense</b>						
Current Tax	61.45	35.27	26.84	125.60	100.18	108.66
Deferred Tax	(4.00)	4.86	3.39	4.83	10.47	12.63
<b>Profit for the period</b>	<b>108.32</b>	<b>120.70</b>	<b>95.47</b>	<b>352.62</b>	<b>350.39</b>	<b>391.76</b>
<b>Other Comprehensive Income (OCI)</b>						
Items that will not be reclassified subsequently to profit or loss	(1.14)	(1.80)	(0.50)	(3.43)	(1.49)	(1.97)
Income tax relating to items that will not be reclassified to profit or loss	0.40	0.63	0.18	1.20	0.52	0.69
<b>Other Comprehensive Income for the year, net of tax</b>	<b>(0.74)</b>	<b>(1.17)</b>	<b>(0.32)</b>	<b>(2.23)</b>	<b>(0.97)</b>	<b>(1.28)</b>
<b>Total Comprehensive Income for the period</b>	<b>107.58</b>	<b>119.53</b>	<b>95.15</b>	<b>350.39</b>	<b>349.42</b>	<b>390.48</b>
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.54	17.54	17.69	17.54	17.69	17.54
Other Equity						2,124.54
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	12.41	13.83	10.85	40.41	39.81	44.51
(b) Diluted - in ₹	12.41	13.83	10.85	40.41	39.81	44.51

**Notes :**

- The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 5 February 2020.
- Statutory Auditors have carried out Limited Review of the standalone financial results for the quarter and nine month ended 31 December 2019.
- Other income includes :

	3 months ended			9 months ended		Year Ended
	31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
Dividend from subsidiaries (₹ in Crore)	41.86	24.73	16.44	101.30	77.42	77.42

- During the quarter, Nil (nine month 7,500) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ Nil (nine month ₹ 15,000) and securities premium account by ₹ Nil (nine month ₹ 0.93 crores).

- The Company has adopted the modified retrospective approach as per Ind AS 116 - Leases to account for its leases, effective from reporting periods beginning 1 April 2019. This has resulted in recognising right of use assets of ₹ 28.14 crores and a corresponding lease liability of ₹ 31.95 crores by adjusting retained earnings by ₹ 2.48 crores (net of deferred tax of ₹ 1.33 crores) as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from rent to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. Due to this change, current quarter profit before tax is higher by ₹ 0.02 crores (nine month is lower by ₹ 0.10 crores). To this extent, performance for the current period ended 31 December 2019 is not comparable with previous period results.

- The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

- Pursuant to a fire incident on 31 August 2019 at Guwahati plant, certain property, plant and equipment and inventory were damaged. The Company has lodged an initial estimate of loss with the insurance company and the survey is currently in process. The Company has recorded a loss of ₹ 23.27 crores towards impairment of part of property, plant and equipment and inventory arising from the incident. The Company has also recognised a minimum insurance claim receivable of ₹ 21.86 crores in the current nine month, for which auditor has given modified opinion. However, Company is confident of receiving the said claim. The aforementioned loss and the income from insurance claim receivable has been presented under exceptional item in the financial result with a net impact of ₹ 1.41 crores. The Company is in process of determining its final claim and will make adjustments to the estimated loss when the assessment is completed.

- Figures for the previous period's have been regrouped, wherever necessary, to correspond with the figures of the current period.

By order of the Board  
For Ajanta Pharma Ltd.

Yogesh M. Agrawal  
Managing Director

Mumbai, 5 February 2020

